US FDA approves Scholar Rock's muscle weakness drug

The FDA approved Scholar Rock's therapy for a rare genetic disorder that causes muscle weakness. The approval is a major regulatory and commercial milestone for Scholar Rock and could materially improve the company's value through access to a rare-disease treatment market.